Fiche publication
Date publication
juillet 2021
Journal
Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOUDALI Lotfi
Tous les auteurs :
Christen C, Belgodère L, Guillot B, Jumeau C, Lorence A, Kerouani-Lafaye G, Brunel L, Turcry F, Monard A, Grudé F, Guyader G, Boudali L, Albin N
Lien Pubmed
Résumé
The arrival of immunotherapies and targeted therapies challenged the authorities to make them available as soon as possible. France has effective tools, such as clinical trials (CTs) and a national early access program (temporary authorizations for use [ATUs] and temporary recommendations for use [RTUs]), allowing the use of innovative drugs, whether or not they have been authorized or used off-label, for cases that have reached a therapeutic impasse.
Mots clés
France, clinical trials, compassionate use trials, data collection, delivery of health care, drugs investigational, empathy, humans, malignant melanoma
Référence
Cancer. 2021 07 1;127(13):2262-2270
